Ahead of a planned Phase III study, Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.
Numerous major global biopharma companies reported first-quarter 2020 earnings. Typically, the COVID-19 pandemic has affected the companies, although not necessarily in a straightforward way. Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted. Here’s a look.
Denmark’s Novo Nordisk paused three clinical trials of concizumab over safety issues. The studies are evaluating the drug for hemophilia A and B.
As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration accepted for Priority Review the Biologics License Application to the FDA for the company’s investigational AAV5 gene therapy, valoctocogene roxaparvovec, for adults with hemophilia A.
BioMarin Pharmaceutical Inc. announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for the company’s investigational AAV gene therapy valoctocogene roxaparvovec for adults with hemophilia A.
Swiss pharma giant Roche’s 10-month journey to complete the acquisition of the gene therapy company Spark Therapeutics was finalized.
Bayer announced a three-year collaboration agreement with Children’s Hospital of Philadelphia (CHOP) for the discovery and development of small molecules to develop a first-in-class oral non-replacement therapy for the treatment of hemophilia A and B.
The Federal Trade Commission staff reviewing Roche’s plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported.
Cambridge, Mass.-based bluebird bio and Bagsvaerd, Denmark-based Novo Nordisk agreed to develop next-generation genome editing therapies for genetic diseases, including hemophilia.
